Lamming G D, Symonds E B
Br J Clin Pharmacol. 1979;8(Suppl 2):217S-222S.
1 Nineteen pregnant patients whose mean arterial pressure (MAP) was persistently greater than or equal to 103.3 mmHg were given labetalol or methyldopa. 2 Singificant falls (P less than 0.001) in BP only occurred in the group treated with labetalol, and daily BP control was better in this group. 3 Two severely hypertensive patients were successfully treated with intravenous labetalol. 4 There was a higher incidence of spontaneous labour in the labetalol group and a significant difference (P less than 0.05) in the Bishop score of the cervix between the two groups. 5 There were no apparent detrimental effects on the foetus antenatally, during labour or post partum. 6 Slight breathlessness in one patient treated with labetalol was the only side-effect observed but drowsiness, headache and postural hypotension were reported in patients receiving methyldopa.
19名平均动脉压(MAP)持续大于或等于103.3 mmHg的孕妇接受了拉贝洛尔或甲基多巴治疗。
仅拉贝洛尔治疗组的血压出现显著下降(P<0.001),且该组的每日血压控制更好。
两名重度高血压患者通过静脉注射拉贝洛尔成功治疗。
拉贝洛尔组自然分娩的发生率较高,两组宫颈Bishop评分存在显著差异(P<0.05)。
对胎儿在产前、分娩期间或产后均无明显有害影响。
接受拉贝洛尔治疗的一名患者出现轻微气喘是观察到的唯一副作用,但接受甲基多巴治疗的患者报告有嗜睡、头痛和体位性低血压。